FLGT

$18.65-$0.06 (-0.32%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$514.8M

28M shares

52-week range

$13.46 – $31.04

30% from low

Sector

SERVICES-MEDICAL LABORATORIES

Exchange

NASDAQ

Change$-77.38

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$352M	+8.5%	$-1.55	$-1.55–$-1.55	—	1
2027	$402M	+14.1%	$-1.15	$-1.15–$-1.15	—	1
2028	$435M	+8.3%	$-0.99	$-0.99–$-0.99	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-30	$-0.46	$-0.58	-26.1%
2026-05-01	$-0.35	$-0.36	-3.4%
2026-02-27	$0.03	$0.16	+433.3%
2025-11-07	$-0.24	$0.14	+158.3%
2025-08-01	$-0.23	$0.07	+130.4%
2025-05-02	$-0.19	$0.04	+121.1%
2025-02-28	$-0.31	$0.04	+112.9%
2024-11-08	$-0.19	$0.31	+263.2%

DCF fair valuemodel estimate

Intrinsic value

$4.56

Price

$18.65

Implied downside

-76%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
FLGTFulgent Genetics, Inc.	$18.65	-0.32%	$530M	—
ARVNArvinas, Inc.	$9.01	+1.58%	$581M	—
AVXLAnavex Life Sciences Corp.	$3.27	-4.11%	$303M	—
BFLYButterfly Network, Inc.	$8.86	-6.24%	$2.4B	—
CDNACareDx, Inc	$47.38	+0.15%

Fulgent Genetics, Inc. Common Stock

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

www.fulgentgenetics.com

Employees: 1,315
IPO / List date: Sep 29, 2016
HQ: EL MONTE, CA

Held by traders on TradeandTell

No one on the platform currently holds FLGT.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	18,000	$286.2K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded FLGT yet.

$FLGT chatter on StockTwits

John@TofuDofuAug 7
$FLGT I spent some time researching head and neck cancers. It appears there are already many drugs available. What makes this company's drug worth developing when there are big name competitors that already have a huge head start in the game?
View on StockTwits ↗
Bob freemam@BobfreeBullishJul 31
$FLGT A turn around company trading at cash value is not going turn around in a quarter. Stock based compensation a bit high but looks like much of that is acquisition related. Looks on track for strong EPS once acquisitions are fully integrated so I'm not going anywhere.
View on StockTwits ↗
John@TofuDofuJul 31
$FLGT Bought this a while back thinking it was a well run company with a good balance sheet. But it does nothing but go down. Will it ever come back to the 40s? Seems like every earnings is a miss and a letdown
View on StockTwits ↗
David Childs@Childs24Jul 30
$FLGT Ouch. nasty looking AH action - Reminds me of last ER…
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderJul 30
https://www.marketbeat.com/earnings/reports/2026-7-30-fulgent-genetics-inc-stock/ $FLGT Fulgent Genetics Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsJul 30
$FLGT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.05 down -69.35% YoY • Reported revenue of $85.39M up 4.38% YoY
View on StockTwits ↗
John Naugle@jf152BullishJul 28
$FLGT 1.) You liked your own post? Pathetic. 2.) Why cover your short position if it's junk? You're a lying manipulator.
View on StockTwits ↗
Rui Azevedo@standupwallJul 28
$FLGT This stock will be a multi bagger in the next couple of years.
View on StockTwits ↗
James Bond@SexydreamBearishJul 28
$FLGT I closed out all my short positions on this junk stock today and this concludes my entire program with this holding. It was a good one to say the least. It was nice to argue and troll with yall the last few years. Now that I'm permanently done with this stock, I hope you all make a ton of money in the market. It is unlikely I'll come back here, but maybe I'll check in once in a while to say hi. Good luck trading and be healthy. (I'm still bearish on this junk stock tho)
View on StockTwits ↗
James Bond@SexydreamBearishJul 27
$FLGT post earnings prediction? I say $15. Unlike class clown @jf152 who think this is going to 100. Hahahahahahhahah he will be saying this in 5 years too when stock is at $5
View on StockTwits ↗
Rui Azevedo@standupwallBullishJul 22
$FLGT Investment houses will recommend the stock when momentum kicks in and the stock goes north 40 usd.
View on StockTwits ↗
John Naugle@jf152BullishJul 21
@Sexydream $FLGT was up 1.38% today. WTF are you hallucinating?
View on StockTwits ↗
James Bond@SexydreamBearishJul 21
$FLGT again, market is roaring and junk flgt is..... You guessed it! @jf152 is a perpetual loser, holding this bag until he's 85 yo. He's gonna still be saying $100 in 1 year! 🤣🤣🤣
View on StockTwits ↗
Squeezy@TheRealShortSqueezyBullishJul 21
🚨 $INBS : Today's FDA Progress Update 🇺🇸 Today's news: Intelligent Bio Solutions announced it has successfully completed precision testing, another important step toward its FDA 510(k) submission and planned U.S. commercial launch. 🧪 Latest Update 🔹 Successfully completed precision testing, adding another key validation study to its FDA 510(k) submission. 🔹 The submission package now includes Precision, Method Comparison, Cut off, and Interference studies. 🔹 More than 1,600 tests were completed across 3 production runs and 3 independent testing sites, demonstrating consistent performance. 🔹 Targeting the U.S. drug screening market, estimated at over $5.8B today and projected to surpass $11.2B by 2034, with its fingerprint-based drug testing technology. 🔹 Results are available in under 10 minutes, with sample collection taking only seconds and no blood, urine, or saliva required. Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers:$CODX $FLGT $DGX $LH
View on StockTwits ↗
James Bond@SexydreamBearishJul 20
$FLGT @jf152 Hello $19. I'll let the stock price do the talking. Too bz making $$$ shorting this junk stock, it's really the gift that keeps on giving. Thanks to losers like you I'm getting rich. Hehehehehe
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.